Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863534 | 0.85 | TSHR (0.56) | TSHRPOLBCYP1A2CYP2C19HTT | |
| SCHEMBL2864762 | 0.80 | TP53 (0.52) | POLBLMNATDP1 | |
| SCHEMBL2861530 | 0.73 | BPTF (0.50) | TSHRPOLBHPGDLMNABPTF | |
| SCHEMBL8085608 | 0.72 | TSHR (0.78) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL3363897 | 0.70 | POLB (0.74) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL3363893 | 0.70 | POLB (0.74) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL2858045 | 0.70 | TSHR (0.74) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL26603110 | 0.69 | TSHR (0.78) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL30626009 | 0.69 | TSHR (0.78) | TSHRKMT2APOLBGRK2CTDSP1 | |
| SCHEMBL26603162 | 0.69 | TSHR (0.78) | TSHRKMT2APOLBGRK2CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1827434-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | Amgen Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | TSHR 1963/4885KMT2A 3151/4885POLB 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.